Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tesaglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 19/20 | 1.00 |
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | PPARD | Q03181 | 10/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tesaglitazar SCHEMBL13602606 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL5368994 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL3162078 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL16594 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL7211452 | 0.98 | PPARA (0.96) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL7211447 | 0.97 | PPARA (0.94) | PPARAPPARGPPARD | |
| SCHEMBL3262954 | 0.91 | PPARA (0.83) | PPARAPPARGPPARD | |
| SCHEMBL3262951 | 0.91 | PPARA (0.83) | PPARAPPARGPPARD | |
| SCHEMBL5993854 | 0.90 | PPARA (0.82) | PPARAPPARGPPARD | |
| SCHEMBL28649134 | 0.90 | PPARA (0.82) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814582-A4 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | INTERCEPT PHARMACEUTICALS INC (US) | 2009-07-15 | — | — | EP | claimed |
| EP-1814582-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | Intercept Pharmaceuticals Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060252670-A1 | Method of reducing drug-induced adverse side effects in a patient | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-11-09 | — | — | US | claimed |
| WO-2006044391-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-8486621-B2 | Nucleic acid-based matrixes | CORNELL RESEARCH FOUNDATION, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120045430-A1 | DENDRIMER-LIKE MODULAR DELIVERY VECTOR | CORNELL UNIVERSITY | 2012-02-23 | — | — | US | disclosed |
| US-20120040397-A1 | Photo-Crosslinked Nucleic Acid Hydrogels | CORNELL UNIVERSITY | 2012-02-16 | — | — | US | disclosed |
| EP-2324045-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | Cornell University (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100136614-A1 | Dendrimer-like modular delivery vector | LUO DAN | 2010-06-03 | — | — | US | disclosed |
| WO-2010017264-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | CORNELL UNIVERSITY (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-1814582-A4 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | INTERCEPT PHARMACEUTICALS INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080280955-A1 | Methods and compositions for screening and treatment of disorders of blood glucose regulation | PERLEGEN SCIENCES, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1931805-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATMENT OF DISORDERS OF BLOOD GLUCOSE REGULATION | Perlegen Sciences, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1814582-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | Intercept Pharmaceuticals Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070148246-A1 | Nucleic Acid-Based Matrixes | CORNELL RESEARCH FOUNDATION INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070117177-A1 | Nucleic Acid-Based Matrixes for Protein Production | CORNELL RESEARCH FOUNDATION, INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007038670-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATMENT OF DISORDERS OF BLOOD GLUCOSE REGULATION | PERLEGEN SCIENCES, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20060252670-A1 | Method of reducing drug-induced adverse side effects in a patient | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006044391-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |